Unknown

Dataset Information

0

Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.

ABSTRACT: BACKGROUND: Ovarian cancer is a heterogeneous disease and prognosis for apparently similar cases of ovarian cancer varies. Recurrence of the disease in early stage (FIGO-stages I-II) serous ovarian cancer results in survival that is comparable to those with recurrent advanced-stage disease. The aim of this study was to investigate if there are specific genomic aberrations that may explain recurrence and clinical outcome. METHODS: Fifty-one women with early stage serous ovarian cancer were included in the study. DNA was extracted from formalin fixed samples containing tumor cells from ovarian tumors. Tumor samples from thirty-seven patients were analysed for allele-specific copy numbers using OncoScan single nucleotide polymorphism arrays from Affymetrix and the bioinformatic tool Tumor Aberration Prediction Suite. Genomic gains, losses, and loss-of-heterozygosity that associated with recurrent disease were identified. RESULTS: The most significant differences (p?

SUBMITTER: Skirnisdottir I 

PROVIDER: S-EPMC3495882 | biostudies-other | 2012

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.

Skirnisdottir Ingiridur I   Mayrhofer Markus M   Rydåker Maria M   Akerud Helena H   Isaksson Anders A  

BMC cancer 20120912

<h4>Background</h4>Ovarian cancer is a heterogeneous disease and prognosis for apparently similar cases of ovarian cancer varies. Recurrence of the disease in early stage (FIGO-stages I-II) serous ovarian cancer results in survival that is comparable to those with recurrent advanced-stage disease. The aim of this study was to investigate if there are specific genomic aberrations that may explain recurrence and clinical outcome.<h4>Methods</h4>Fifty-one women with early stage serous ovarian cance  ...[more]

Similar Datasets

Unknown Lipid Alterations in Early-Stage High-Grade Serous Ovarian Cancer.
| S-EPMC9048792 | biostudies-literature
Unknown The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
| S-EPMC7612959 | biostudies-literature
Unknown KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
| S-EPMC4095747 | biostudies-other
Unknown Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
| S-EPMC3050629 | biostudies-literature
Unknown Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer.
| S-EPMC7823988 | biostudies-literature
Unknown Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas.
| S-EPMC2677417 | biostudies-literature
Unknown Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging.
| S-EPMC7463791 | biostudies-literature
Unknown Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q.
| S-EPMC2940597 | biostudies-literature
Transcriptomics Stage III serous ovarian adenocarcinomas
2008-08-12 | GSE12418 | GEO
Unknown Prognostic Significance of the Loss of Heterozygosity of <i>KRAS</i> in Early-Stage Lung Adenocarcinoma.
| S-EPMC9098994 | biostudies-literature